03772nam a22005295i 4500001001800000003000900018005001700027007001500044008004100059020003700100024003500137050001400172072001600186072002300202072001500225245022600240250001800466264007200484300004400556336002600600337002600626338003600652347002400688505120000712520065001912650002502562650003002587650003102617650003002648650003402678650002502712650002502737650004602762650003202808650003302840650002502873700008502898710003402983773002603017776003603043776003603079776003603115856004603151912001403197912001403211999001703225978-981-97-7380-0DE-He21320251030113247.0cr nn 008mamaa241026s2024    si |    s    |||| 0|eng d  a97898197738009978-981-97-7380-07 a10.1007/978-981-97-7380-02doi 4aRM300-666 7aMMG2bicssc 7aMED0710002bisacsh 7aMKG2thema10aAngiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockersh[electronic resource] :bA Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview /cedited by Mukesh Nandave.  a1st ed. 2024. 1aSingapore :bSpringer Nature Singapore :bImprint: Springer,c2024.  aXIV, 602 p. 25 illus.bonline resource.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda0 aChapter 1_ Introduction of the renin-angiotensin-aldosterone system (RAAS) -- Chapter 2_ Role of anti-hypertensive agents in cardiovascular disorders -- Chapter 3_ (ACE) Angiotensin-converting enzyme inhibitors: Preferred RAAS inhibitor in high-risk patients as compared to angiotensin receptor blockers (ARBs) -- Chapter 4_ Role of (ACE) angiotensin-converting enzyme inhibitors in transforming renin–angiotensin system -- Chapter 5_ The effect of (ACE) Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers on insulin resistance in hypertensive patients -- Chapter 6_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure -- Chapter 7_ Immunomodulator activity of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients -- Chapter 8_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peripheral artery disease -- Chapter 9_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in covid-19 patients -- Chapter 10_ Recent trends in the management of hypertension through RAAS inhibition.  aThe auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage. 0aPharmacology.967844 0aPharmacovigilance.974275 0aMedicinexResearch.962598 0aBiologyxResearch.965629 0aClinical biochemistry.967825 0aTherapeutics.97008714aPharmacology.96784424aDrug Safety and Pharmacovigilance.97427624aBiomedical Research.96563324aMedical Biochemistry.96782824aTherapeutics.9700871 aNandave, Mukesh.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt9747242 aSpringerLink (Online service)0 tSpringer Nature eBook08iPrinted edition:z978981977379408iPrinted edition:z978981977381708iPrinted edition:z978981977382440uhttps://doi.org/10.1007/978-981-97-7380-0  aZDB-2-SME  aZDB-2-SXM  c64518d64518